Literature DB >> 24892773

PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Ellen M McDonagh1, Sotiria Boukouvala, Eleni Aklillu, David W Hein, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24892773      PMCID： PMC4109976          DOI： 10.1097/FPC.0000000000000062

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  197 in total

Review 1.  Structures of human arylamine N-acetyltransferases.

Authors:  D M Grant
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 2.  Arylamine N-acetyltransferases: what we learn from genes and genomes.

Authors:  Sotiria Boukouvala; Giannoulis Fakis
Journal:  Drug Metab Rev       Date:  2005       Impact factor: 4.518

3.  Association analysis of drug metabolizing enzyme gene polymorphisms in HIV-positive patients with co-trimoxazole hypersensitivity.

Authors:  M Pirmohamed; A Alfirevic; J Vilar; A Stalford; E G Wilkins; E Sim; B K Park
Journal:  Pharmacogenetics       Date:  2000-11

4.  Do selected drugs increase the risk of lupus? A matched case-control study.

Authors:  W Marieke Schoonen; Sara L Thomas; Emily C Somers; Liam Smeeth; Joseph Kim; Stephen Evans; Andrew J Hall
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 5.  Arylamine N-acetyltransferases: structural and functional implications of polymorphisms.

Authors:  Edith Sim; Nathan Lack; Chan-Ju Wang; Hilary Long; Isaac Westwood; Elizabeth Fullam; Akane Kawamura
Journal:  Toxicology       Date:  2008-09-12       Impact factor: 4.221

6.  Variability in drug metabolizing enzyme activity in HIV-infected patients.

Authors:  Amanda E Jones; Kevin C Brown; Rebecca E Werner; Karl Gotzkowsky; Andrea Gaedigk; Mike Blake; David W Hein; Charles van der Horst; Angela D M Kashuba
Journal:  Eur J Clin Pharmacol       Date:  2010-01-19       Impact factor: 2.953

Review 7.  Influence of polymorphic N-acetyltransferases on non-malignant spontaneous disorders and on response to drugs.

Authors:  J M Ladero
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

8.  Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies?

Authors:  L Le Marchand; L Sivaraman; A A Franke; L J Custer; L R Wilkens; A F Lau; R V Cooney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1996-06       Impact factor: 4.254

9.  N-acetyl transferase 2 and cytochrome P450 2E1 genes and isoniazid-induced hepatotoxicity in Brazilian patients.

Authors:  N P C Santos; S M Callegari-Jacques; A K C Ribeiro Dos Santos; C A Silva; A C R Vallinoto; D C R O Fernandes; D C de Carvalho; S E B Santos; M H Hutz
Journal:  Int J Tuberc Lung Dis       Date:  2013-01-31       Impact factor: 2.373

10.  Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia.

Authors:  Hélène Magalon; Etienne Patin; Frédéric Austerlitz; Tatyana Hegay; Almaz Aldashev; Lluís Quintana-Murci; Evelyne Heyer
Journal:  Eur J Hum Genet       Date:  2007-11-28       Impact factor: 4.246
View more
  45 in total

1.  Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype.

Authors:  David W Hein; Mark A Doll
Journal:  Arch Toxicol       Date:  2017-05-18       Impact factor: 5.153

2.  N-acetyltransferase 2 enzyme genotype-phenotype discordances in both HIV-negative and HIV-positive Nigerians.

Authors:  Olayinka A Kotila; Olufunmilayo I Fawole; Olufunmilayo I Olopade; Adejumoke I Ayede; Adeyinka G Falusi; Chinedum P Babalola
Journal:  Pharmacogenet Genomics       Date:  2019-07       Impact factor: 2.089

3.  Effect of acetaminophen on sulfamethazine acetylation in male volunteers.

Authors:  I M Tahir; T Iqbal; S Saleem; H Mehboob; N Akhter; M Riaz
Journal:  Int J Immunopathol Pharmacol       Date:  2015-10-30       Impact factor: 3.219

4.  Role of the N-acetylation polymorphism in solithromycin metabolism.

Authors:  David W Hein; Mark A Doll
Journal:  Pharmacogenomics       Date:  2017-04-24       Impact factor: 2.533

5.  Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4'-methylene bis (2-chloroaniline) biotransformation.

Authors:  David W Hein; Xiaoyan Zhang; Mark A Doll
Journal:  Toxicol Lett       Date:  2017-11-24       Impact factor: 4.372

6.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

Review 7.  Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Authors:  Karla Claudio-Campos; Jorge Duconge; Carmen L Cadilla; Gualberto Ruaño
Journal:  Drug Metab Pers Ther       Date:  2015-06

8.  Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes.

Authors:  Mark A Doll; David W Hein
Journal:  Arch Toxicol       Date:  2017-05-17       Impact factor: 5.153

Review 9.  Genotype-Guided Hydralazine Therapy.

Authors:  Kimberly S Collins; Anthony L J Raviele; Amanda L Elchynski; Alexander M Woodcock; Yang Zhao; Rhonda M Cooper-DeHoff; Michael T Eadon
Journal:  Am J Nephrol       Date:  2020-09-14       Impact factor: 3.754

10.  Dose evaluation of intravenous metamizole (dipyrone) in infants and children: a prospective population pharmacokinetic study.

Authors:  Victoria C Ziesenitz; Frédérique Rodieux; Andrew Atkinson; Carole Borter; Julia A Bielicki; Manuel Haschke; Urs Duthaler; Fabio Bachmann; Thomas O Erb; Nicolas Gürtler; Stefan Holland-Cunz; Johannes N van den Anker; Verena Gotta; Marc Pfister
Journal:  Eur J Clin Pharmacol       Date:  2019-08-07       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.